Baseline characteristics (full analysis set)
| Characteristic . | Ticagrelor group (n = 101) . | Placebo group (n = 92) . |
|---|---|---|
| Age, y | ||
| Mean ± SD | 10.4 ± 4.1 | 10.1 ± 3.8 |
| Median (minimum, maximum) | 10.0 (3.0, 17.0) | 10.5 (3.0, 17.0) |
| Age group, n (%) | ||
| <12 y | 61 (60) | 54 (59) |
| ≥12 y | 40 (40) | 38 (41) |
| Female sex, n (%) | 48 (48) | 43 (47) |
| Race, n (%) | ||
| Black or African American | 60 (59) | 51 (55) |
| White | 25 (25) | 21 (23) |
| Asian | 15 (15) | 15 (16) |
| Other | 1 (1.0) | 5 (5) |
| Geographic region, n (%) | ||
| Ghana, Kenya, South Africa, Tanzania, Uganda | 45 (45) | 44 (48) |
| Egypt, Lebanon, Turkey | 21 (21) | 18 (20) |
| India | 15 (15) | 15 (16) |
| Belgium, Greece, Italy, Spain, United Kingdom | 11 (11) | 8 (9) |
| United States | 4 (4) | 4 (4) |
| Brazil | 5 (5) | 3 (3) |
| SCD genotype, n (%) | ||
| HbSS | 87 (86) | 83 (90) |
| HbS/β0 | 13 (13) | 9 (10) |
| Missing* | 1 (1) | 0 |
| No. of vaso-occlusive crises in past 12 mo, n (%) | ||
| ≤1† | 0 | 1 (1) |
| 2 to 4 | 99 (98) | 89 (97) |
| >4 | 2 (2) | 2 (2) |
| Patients using hydroxyurea at baseline, n (%) | 65 (64) | 58 (63) |
| Characteristic . | Ticagrelor group (n = 101) . | Placebo group (n = 92) . |
|---|---|---|
| Age, y | ||
| Mean ± SD | 10.4 ± 4.1 | 10.1 ± 3.8 |
| Median (minimum, maximum) | 10.0 (3.0, 17.0) | 10.5 (3.0, 17.0) |
| Age group, n (%) | ||
| <12 y | 61 (60) | 54 (59) |
| ≥12 y | 40 (40) | 38 (41) |
| Female sex, n (%) | 48 (48) | 43 (47) |
| Race, n (%) | ||
| Black or African American | 60 (59) | 51 (55) |
| White | 25 (25) | 21 (23) |
| Asian | 15 (15) | 15 (16) |
| Other | 1 (1.0) | 5 (5) |
| Geographic region, n (%) | ||
| Ghana, Kenya, South Africa, Tanzania, Uganda | 45 (45) | 44 (48) |
| Egypt, Lebanon, Turkey | 21 (21) | 18 (20) |
| India | 15 (15) | 15 (16) |
| Belgium, Greece, Italy, Spain, United Kingdom | 11 (11) | 8 (9) |
| United States | 4 (4) | 4 (4) |
| Brazil | 5 (5) | 3 (3) |
| SCD genotype, n (%) | ||
| HbSS | 87 (86) | 83 (90) |
| HbS/β0 | 13 (13) | 9 (10) |
| Missing* | 1 (1) | 0 |
| No. of vaso-occlusive crises in past 12 mo, n (%) | ||
| ≤1† | 0 | 1 (1) |
| 2 to 4 | 99 (98) | 89 (97) |
| >4 | 2 (2) | 2 (2) |
| Patients using hydroxyurea at baseline, n (%) | 65 (64) | 58 (63) |